|
1
|
Tew KD, Colvin M and Chabner BA:
Alkylating agentsCancer Chemotherapy and Biotherapy: Principles and
Practice. Chabner BA and Longo DL: Lippincott-Raven Publishers;
Philadelphia: pp. 297–317. 1996
|
|
2
|
Fu D, Calvo JA and Samson LD: Balancing
repair and tolerance of DNA damage caused by alkylating agents. Nat
Rev Cancer. 12:104–120. 2012.PubMed/NCBI
|
|
3
|
Geleziunas R, McQuillan A, Malapetsa A,
Hutchinson M, Kopriva D, Wainberg MA, Hiscott J, Bramson J and
Panasci L: Increased DNA synthesis and repair-enzyme expression in
lymphocytes from patients with chronic lymphocytic leukemia
resistant to nitrogen mustards. J Natl Cancer Inst. 83:557–564.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Drabløs F, Feyzi E, Aas PA, Vaagbø CB,
Kavli B, Bratlie MS, Peña-Diaz J, Otterlei M, Slupphaug G and
Krokan HE: Alkylation damage in DNA and RNA - repair mechanisms and
medical significance. DNA Repair (Amst). 3:1389–1407. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wiencke JK and Wiemels J: Genotoxicity of
1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Mutat Res. 339:91–119.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Povirk LF and Shuker DE: DNA damage and
mutagenesis induced by nitrogen mustards. Mutat Res. 318:205–226.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Friedman HS, Kerby T and Calvert H:
Temozolomide and treatment of malignant glioma. Clin Cancer Res.
6:2585–2597. 2000.PubMed/NCBI
|
|
8
|
Stupp R, Gander M, Leyvraz S and Newlands
E: Current and future developments in the use of temozolomide for
the treatment of brain tumours. Lancet Oncol. 2:552–560. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mason WP and Cairncross JG: Drug Insight:
Temozolomide as a treatment for malignant glioma - impact of a
recent trial. Nat Clin Pract Neurol. 1:88–95. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fink D, Aebi S and Howell SB: The role of
DNA mismatch repair in drug resistance. Clin Cancer Res. 4:1–6.
1998.PubMed/NCBI
|
|
11
|
Fan CH, Liu WL, Cao H, Wen C, Chen L and
Jiang G: O6-methylguanine DNA methyltransferase as a
promising target for the treatment of temozolomide-resistant
gliomas. Cell Death Dis. 4:e8762013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fahrer J and Kaina B:
O6-methylguanine-DNA methyltransferase in the defense
against N-nitroso compounds and colorectal cancer. Carcinogenesis.
34:2435–2442. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chaney SG and Sancar A: DNA repair:
Enzymatic mechanisms and relevance to drug response. J Natl Cancer
Inst. 88:1346–1360. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Panasci L, Paiement JP, Christodoulopoulos
G, Belenkov A, Malapetsa A and Aloyz R: Chlorambucil drug
resistance in chronic lymphocytic leukemia: The emerging role of
DNA repair. Clin Cancer Res. 7:454–461. 2001.PubMed/NCBI
|
|
15
|
Bowden NA: Nucleotide excision repair: Why
is it not used to predict response to platinum-based chemotherapy?
Cancer Lett. 346:163–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Martin SA, Lord CJ and Ashworth A:
Therapeutic targeting of the DNA mismatch repair pathway. Clin
Cancer Res. 16:5107–5113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamauchi T, Ogawa M and Ueda T:
Carmustine-resistant cancer cells are sensitized to temozolomide as
a result of enhanced mismatch repair during the development of
carmustine resistance. Mol Pharmacol. 74:82–91. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamamoto S, Yamauchi T, Kawai Y, Takemura
H, Kishi S, Yoshida A, Urasaki Y, Iwasaki H and Ueda T:
Fludarabine-mediated circumvention of cytarabine resistance is
associated with fludarabine triphosphate accumulation in
cytarabine-resistant leukemic cells. Int J Hematol. 85:108–115.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Esteller M, Garcia-Foncillas J, Andion E,
Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG:
Inactivation of the DNA-repair gene MGMT and the clinical response
of gliomas to alkylating agents. N Engl J Med. 343:1350–1354. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shrivastav N, Li D and Essigmann JM:
Chemical biology of mutagenesis and DNA repair: Cellular responses
to DNA alkylation. Carcinogenesis. 31:59–70. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fiumicino S, Martinelli S, Colussi C,
Aquilina G, Leonetti C, Crescenzi M and Bignami M: Sensitivity to
DNA cross-linking chemotherapeutic agents in mismatch
repair-defective cells in vitro and in xenografts. Int J Cancer.
85:590–596. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Loeber R, Michaelson E, Fang Q, Campbell
C, Pegg AE and Tretyakova N: Cross-linking of the DNA repair
protein O6-alkylguanine DNA alkyltransferase to DNA in
the presence of antitumor nitrogen mustards. Chem Res Toxicol.
21:787–795. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Quinn JA, Jiang SX, Reardon DA, Desjardins
A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD,
Sampson JH, et al: Phase II trial of temozolomide plus
O6-benzylguanine in adults with recurrent,
temozolomide-resistant malignant glioma. J Clin Oncol.
27:1262–1267. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Adams DM, Zhou T, Berg SL, Bernstein M,
Neville K and Blaney SMChildren's Oncology Group: Phase 1 trial of
O6-benzylguanine and BCNU in children with CNS tumors: A
Children's Oncology Group study. Pediatr Blood Cancer. 50:549–553.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Balaña C, Ramirez JL, Taron M, Roussos Y,
Ariza A, Ballester R, Sarries C, Mendez P, Sanchez JJ and Rosell R:
O6-methyl-guanine-DNA methyltransferase methylation in
serum and tumor DNA predicts response to
1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus
cisplatin in glioblastoma multiforme. Clin Cancer Res. 9:1461–1468.
2003.PubMed/NCBI
|
|
27
|
Aquilina G, Ceccotti S, Martinelli S,
Hampson R and Bignami M:
N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea sensitivity in
mismatch repair-defective human cells. Cancer Res. 58:135–141.
1998.PubMed/NCBI
|
